Advanced Biomed Inc. (ADVB) Fair Value 2026

ADVB · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, Advanced Biomed Inc. (ADVB) trades at $9.57, versus a $14.55 median fair value across its 2 active models — 52.1% above the current price. QOC: 5.0/10. Value Trap Risk: 13/100 (SAFE). 2/13 models active.

Key Facts

Ticker
ADVB
Price
$9.57
Quality Score
5.0/10
Value Trap Risk
13/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +167.4% upside with 51% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Advanced Biomed Inc. (ADVB) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Advanced Biomed Inc. (ADVB) appears undervalued as of : the median of 2 independent fair value estimates is $14.55, 52.1% above the current price of $9.57. Estimates range from $3.52 to $25.59. ADVB scores 5.0/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ADVB’s +52.1% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Advanced Biomed Inc. Stock in 2026? →

What Fair Value Does Each Model Give ADVB?

2 Intrinsic Value Models vs. Current Price ($9.57)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $25.59 +167.4%
Asset-Based · Medium Conviction
 $3.52 -63.3%

All Models Active

All 2 models are displayed above.

What Is Advanced Biomed Inc. (ADVB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Advanced Biomed Inc.'s intrinsic value is estimated at a median $14.55, showing conflicting signals at the current price of $9.57. While the median implied return is +52.1%, model disagreement is elevated with a gap of +230.7% between the most bullish and bearish estimates. The most optimistic model, ML-RIV, places fair value at $25.59 (+167.4%), while Dynamic NAV — the most conservative — estimates $3.52 (-63.3%). This +230.7% gap reflects genuine analytical uncertainty about Advanced Biomed Inc.'s intrinsic worth.

What Do the Models Say About ADVB?

2 of 13 models are currently active for ADVB. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for ADVB is $14.55 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ADVB Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, ADVB ranks #41 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

As a pharmaceutical industry, Advanced Biomed Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ADVB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ADVB a Value Trap?

CirclFi's Value Trap algorithm assigns ADVB a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Advanced Biomed Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Advanced Biomed Inc.'s fundamental quality profile registers 5.0/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +230.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ADVB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ADVB's 2 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Advanced Biomed Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

10 related Diagnostics & Research stocks with 13-model coverage

XWELXWELL, Inc.QOC 5.5BIAFbioAffinity Technologies, Inc.QOC 5.0OPKOPKO Health, Inc.QOC 5.6ISPCiSpecimen Inc.QOC 4.8QUCYQuantum Cyber N.V.QOC 5.6FRNMFreenome, Inc.QOC 4.8MEDPMedpace Holdings, Inc.QOC 9.3LHLabcorp Holdings Inc.QOC 7.7RDNTRadNet, Inc.QOC 6.7IDXXIDEXX Laboratories, Inc.QOC 9.5

Read investment analysis: XWEL · BIAF · OPK · ISPC · QUCY · FRNM · MEDP · LH · RDNT · IDXX

Which Other Stocks Have a Similar Quality Score to ADVB?

7 companies across all industries closest to ADVB’s Quality of Company score of 5.0/10.

GAMGGlobal Asset Management Group IQOC 5.0ARXSArxis, Inc.QOC 5.0SORSource CapitalQOC 5.0VVOSVivos Therapeutics, Inc.QOC 5.0XXII22nd Century Group, Inc.QOC 5.0ACIUAC Immune SAQOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GAMG · ARXS · SOR · VVOS · XXII · ACIU · NVDA

What Else Do Investors Ask About Advanced Biomed Inc.’s Valuation?

What is Advanced Biomed Inc.'s intrinsic value in 2026?

CirclFi puts Advanced Biomed Inc. (ADVB)'s intrinsic value at $14.55 — the median of 2 independent model estimates as of 2026-08-27, ranging from $3.52 to $25.59. The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ADVB overvalued or undervalued right now?

At $9.57, 1 of 2 active models suggest ADVB may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $14.55, 52.1% above the current price of $9.57 — a consensus view that ADVB is undervalued. The assessment depends on which methodology best fits Advanced Biomed Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 5.0 mean for ADVB?

Advanced Biomed Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ADVB?

CirclFi analyzes ADVB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ADVB a value trap in 2026?

Advanced Biomed Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Advanced Biomed Inc. (ADVB) has a median fair value of $14.55 — 52.1% above the current price of $9.57 — as of 2026-08-27.” Source: circlfi.com/stock/ADVB/ · Methodology
Primary sources for this ADVB valuation
  • Financial statements: Advanced Biomed Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001941029) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ADVB as of ; valuations recomputed .